Earnings summaries and quarterly performance for ZyVersa Therapeutics.
Executive leadership at ZyVersa Therapeutics.
Board of directors at ZyVersa Therapeutics.
Research analysts covering ZyVersa Therapeutics.
Recent press releases and 8-K filings for ZVSA.
ZyVersa Therapeutics Reports Q3 2025 Financial Results
ZVSA
Earnings
Profit Warning
- ZyVersa Therapeutics reported net losses of approximately $19.8 million for the three months ended September 30, 2025, a significant increase from $2.4 million in the prior year, primarily due to an $18.6 million impairment of research and development.
- The company reported $0.5 million in cash on hand as of September 30, 2025, and stated that its cash and cash equivalents are expected to be sufficient only to fund operating expenses on a month-to-month basis, necessitating additional financing.
- ZyVersa raised approximately $2.05 million in Q3 2025, bringing the year-to-date total to $4.05 million.
- For the three months ended September 30, 2025, research and development expenses decreased by 16.3% to $0.4 million, and general and administrative expenses decreased by 5.1% to $1.7 million, compared to the same period in the prior year.
Nov 19, 2025, 9:25 PM
ZyVersa Therapeutics Delisting Notice and Appeal Process
ZVSA
Delisting/Listing Issues
- Nasdaq notified ZyVersa Therapeutics that its stock closed below $1.00 for 30 consecutive business days, triggering a delisting risk.
- The company's recent reverse stock splits (1-for-35 on December 4, 2023 and 1-for-10 on April 24, 2024) rendered it ineligible for the usual cure period.
- The company intends to appeal the delisting decision by requesting a hearing, with an appeal deadline of 4:00 p.m. ET on June 3, 2025, to stay the delisting scheduled for June 5, 2025.
May 30, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more